BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30343532)

  • 1. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
    Micevic G; Thakral D; McGeary M; Bosenberg MW
    Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
    Amini M; Hejazi M; Ghorban K; Mokhtarzadeh A; Baradaran B
    Gene; 2021 Mar; 772():145376. PubMed ID: 33359128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.
    Faiena I; Astrow SH; Elashoff DA; Jain R; Bot A; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A
    Cancer Immunol Immunother; 2019 May; 68(5):743-751. PubMed ID: 30790015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
    Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
    Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
    Madore J; Strbenac D; Vilain R; Menzies AM; Yang JY; Thompson JF; Long GV; Mann GJ; Scolyer RA; Wilmott JS
    Clin Cancer Res; 2016 Aug; 22(15):3915-23. PubMed ID: 26960397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
    Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma.
    de Vos L; Carrillo Cano TM; Zarbl R; Klümper N; Ralser DJ; Franzen A; Herr E; Gabrielpillai J; Vogt TJ; Dietrich J; Strieth S; Landsberg J; Dietrich D
    J Immunother; 2022 Sep; 45(7):324-334. PubMed ID: 35862127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
    Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
    J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.
    Li X; Wang Z; Huang J; Luo H; Zhu S; Yi H; Zheng L; Hu B; Yu L; Li L; Xie J; Zhu N
    FEBS Open Bio; 2019 Jun; 9(6):1063-1070. PubMed ID: 31090214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
    Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
    Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
    Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
    Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma.
    Han J; Xu X; Liu Z; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Nov; 88():106971. PubMed ID: 33182029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
    Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
    Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Nicoli D; Farnetti E; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
    Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J
    Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
    Wang YF; Liu F; Sherwin S; Farrelly M; Yan XG; Croft A; Liu T; Jin L; Zhang XD; Jiang CC
    J Invest Dermatol; 2018 Apr; 138(4):922-932. PubMed ID: 29174371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.